Julie is the Chief Executive Officer and Director at Zentalis. Prior to joining Zentalis, she served as the Chief Executive Officer and President of Harpoon Therapeutics, a publicly traded clinical stage oncology company, from November 2021, and a member of its Board of Directors from October 2018, until its acquisition by Merck Sharpe & Dohme in March of 2024. Julie previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a privately held genetics medicine company. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly traded oncology company acquired by Seattle Genetics in 2018. Prior to Cascadian, Julie served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Julie is an independent director of Dynavax Technologies Corporation, Lantheus, and Seismic Therapeutic. Julie received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

Ingmar is Chief Medical Officer of Zentalis. He brings two decades of hematology and oncology experience as a physician and scientist. Prior to joining Zentalis, Ingmar served as Chief Medical Officer of Trillium Therapeutics, a publicly traded clinical stage oncology company, through its acquisition by Pfizer in November 2021, after which he served in clinical development roles at Pfizer, most recently as Development Head, Hematologic Malignancies, Pfizer Global Product Development. Ingmar previously served as the Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals, a publicly traded clinical stage biotechnology company, where he built and led the clinical development organization. From 2013 through 2017, he led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Previously, Ingmar served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Ingmar has authored over 50 publications in the field of hematology and oncology, including several lead authorships in high impact journals such as Nature Medicine, Blood and Leukemia. He received his M.D. and Ph.D. from the University of Lubeck in Germany.

Wendy is the Chief People Officer of Zentalis. She brings over two decades of biopharma experience, including senior roles in human resources and an extensive background in aligning talent with organizations’ overall vision and direction. She was previously Chief People Officer at Harpoon Therapeutics. Before Harpoon, she was VP, Head of People & Culture for IDbyDNA. Wendy previously served in roles of increasing responsibility at Gilead Sciences from 2003 to 2020, most recently as Vice President, Human Resources, and, earlier in her career, at Bio-Rad Laboratories. She received a B.S. in accounting and business/management from the University of California, Riverside, and completed the Global Fellow of Talent Management program at The Wharton School of the University of Pennsylvania.

Kimberly is Chief Strategy Officer at Zentalis Pharmaceuticals. Prior to joining Zentalis, Kimberly was Vice President, US Head of DDR Franchise, Oncology at AstraZeneca. She was responsible for overseeing the strategic direction and cross-functional efforts for LYNPARZA® (olaparib) and other therapies targeting the DDR pathway, which is an important hallmark in ovarian and other cancers. Previously, she held various leadership roles at biopharmaceutical companies including Adaptimmune, Boehringer Ingelheim and GlaxoSmithKline. Kimberly has also served on the Alliance for Regenerative Medicine (ARM) Cell Therapy Advisory Committee and has been recognized by Women in Bio as a Female Pioneer in the Life Sciences. After receiving her Bachelor of Science in Biology from Cornell University, she was a Research Scientist in the Department of Hematology/Medical Oncology at Weill Cornell Medical Center and later pursued Microbiology Graduate Studies at SUNY Upstate Medical Center. Kimberly also received Finance and Marketing Certificates from the Wharton School of the University of Pennsylvania.

Interesting Fact: Kimberly is an avid runner, having completed 5 marathons including New York and Boston!

Mark is Chief Scientific Officer. He has over 20 years of experience in oncology drug development with broad experience ranging from target identification through biomarker development in registrational clinical trials. Prior to joining Zentalis, Mark served as SVP and Head of Biology and Translational Sciences at Ideaya Biosciences from 2018 to October 2022. At Ideaya Mark’s group led clinical translational efforts for the PKC inhibitor darovasertib and the MAT2A inhibitor IDE397 and contributed to three development candidate nominations and one IND. Prior to joining IDEAYA, Mark worked at Genentech for 14 years in positions of increasing responsibility in the Oncology Biomarker Development group, most recently as a Director and Principal Scientist. At Genentech his group was accountable for predictive and pharmacodynamic strategies for candidate therapeutics spanning cancer signaling through immuno-oncology, and was accountable for clinical biomarker strategies for over 20 development stage small molecule and antibody agents. His group developed clinical biomarker strategies for immune doublet combinations with the anti-PDL1 antibody Tecentriq, as well as phase III companion diagnostic strategies for the AKT inhibitor Ipatasertib and the MEK and BRAF inhibitors Cobimetinib and Vemurafenib. Mark also provided strategic leadership for the overall breast cancer biomarker strategy within the broader Roche organization. Prior to joining Genentech, Mark worked at Exelixis from 1999 through 2004 in oncology target identification and validation, including the identification of synthetic lethal interactions with the tumor suppressor gene p53. Mark received his PhD from Stanford University in 1997 for studies on genetic analysis of RAS/MAP kinase signaling. He completed postdoctoral studies at UC Berkeley in the laboratory of Joshua Kaplan. He has authored over 60 peer reviewed scientific manuscripts in journals including Nature Medicine, Nature Communications, Journal of Clinical Oncology, Cancer Cell and Clinical Cancer Research.

Interesting Fact: Mark is an avid hiker and has backpacked over 2000 miles through California's High Sierra mountains.

Andrea Paul is Chief Legal Officer and Corporate Secretary at Zentalis Pharmaceuticals. Previously, Andrea served as General Counsel and Corporate Secretary of LogicBio Therapeutics, Inc., where she led the company’s legal team and served as a key strategic legal partner in the company’s finance, business development and contractual decision-making matters. Before that, she held positions of increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of Vice President, Legal. While at Akebia, Andrea was a key strategic legal partner in the company’s merger with Keryx Biopharmaceuticals, Inc. as well as in the company’s financing and business development transactions. Prior to Akebia, she served as Senior Corporate Counsel at Momenta Pharmaceuticals, Inc. She began her legal career working as an associate at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Sullivan and Cromwell LLP. She received her JD from Harvard Law School, where she served as the Managing Editor of The Harvard Law Review, and her BA in Art History from Columbia University.

Interesting Fact: Andrea is a dedicated Michael Schumacher fan and still watches replays of his F1 races.

Haibo is the Chief Business Officer of Zentalis. He brings over 15 years of biopharma business development, finance, and M&A transaction experience, having most recently served as Senior Vice President of Business Development at Harpoon Therapeutics. While at Harpoon, he played a pivotal role in managing the Company’s acquisition by Merck, which was completed in March 2024. Prior to Harpoon, he served as the Vice President of Business Development at Hummingbird Bioscience, where he was responsible for the company’s end-to-end business development activities. Prior to Hummingbird, Haibo was Director of Business Development at Amgen, where he played a major role in the Teneobio and Five Prime Therapeutics acquisitions, the oncology collaboration with BeiGene, and many clinical collaborations to advance Amgen’s oncology pipeline. He began his career as an M&A consultant at Deloitte, advising on transactions in healthcare and technology. Haibo holds an M.S. in Biotechnology from Johns Hopkins University, an MBA from Duke University, and a BBA from Tsinghua University.